EGFR and non-small cell lung carcinoma: Of note, the FDA currently has approved amivantamab, an EGFR-MET bispecific antibody, for the treatment of patients with locally advanced or metastatic NSCLC patients harboring an EGFR ex20ins mutation who exhibit disease progression during or after platinum-based chemotherapy.